FABP1 and FABP2 as markers of diabetic nephropathy
- PMID: 32922199
- PMCID: PMC7484639
- DOI: 10.7150/ijms.49078
FABP1 and FABP2 as markers of diabetic nephropathy
Abstract
Background: Diabetes mellitus is the leading cause of diabetic nephropathy and a major public health issue worldwide. Approximately 20-30% of patients with type 2 diabetes mellitus (T2DM) have renal impairment. Fatty acid-binding protein 1 (FABP1) is expressed in renal proximal tubule cells and released into urine in response to hypoxia caused by decreased peritubular capillary blood flow, and FABP2 is responsible for the transport of free fatty acids in the intestinal endothelium cells. There is increasing evidence that FABP1 and FABP 2 play a role in the development and progression of chronic kidney disease. The aim of this study was to investigate the relation of circulating FABP1 and FABP2 levels to nephropathy in patients with T2DM. Methods: For this study, 268 subjects with T2DM who were enrolled in a disease management program were stratified according to urinary microalbumin and serum creatinine measurements. The plasma FABP1 and FABP2 concentrations were examined by enzyme-linked immunosorbent assay. Demographic and potential metabolic confounding factors were analyzed with logistic regression to calculate the effects of FABP1 and FABP2 levels on diabetic nephropathy. Results: The FABP1 and FABP2 levels increased in parallel with the advancement of diabetic nephropathy. Increasing concentrations of FABP1 and FABP2 were independently and significantly associated with diabetic nephropathy. Multiple logistic regression analysis revealed FABP1 and FABP2 as an independent association factor for diabetic nephropathy, even after full adjustment of known biomarkers. Furthermore, receiver operating characteristic curve analysis showed that a FABP1 level of >33.8 ng/mL and a FABP2 level of >2.8 ng/mL were associated with diabetic nephropathy. Conclusion: Our results suggest that FABP1 and FABP2 may be novel biomarkers of diabetic nephropathy.
Keywords: Type 2 diabetes mellitus; diabetic nephropathy; fatty acid-binding protein 1; fatty acid-binding protein 2.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
Similar articles
-
Fatty acid binding protein 1 (FABP1) and fatty acid binding protein 2 (FABP2) as a link between diabetic nephropathy and subclinical atherosclerosis in children and adolescents with type 1 diabetes.J Diabetes Complications. 2023 Mar;37(3):108414. doi: 10.1016/j.jdiacomp.2023.108414. Epub 2023 Feb 3. J Diabetes Complications. 2023. PMID: 36758511
-
Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.Nephrology (Carlton). 2017 Jan;22(1):58-64. doi: 10.1111/nep.12719. Nephrology (Carlton). 2017. PMID: 26733347
-
Oxidative stress markers in type 2 diabetes patients with diabetic nephropathy.Clin Exp Nephrol. 2017 Apr;21(2):283-292. doi: 10.1007/s10157-016-1283-7. Epub 2016 May 27. Clin Exp Nephrol. 2017. PMID: 27233502
-
Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature.Diab Vasc Dis Res. 2021 Nov-Dec;18(6):14791641211058856. doi: 10.1177/14791641211058856. Diab Vasc Dis Res. 2021. PMID: 34791910 Free PMC article. Review.
-
The Role of Circulating RBP4 in the Type 2 Diabetes Patients with Kidney Diseases: A Systematic Review and Meta-Analysis.Dis Markers. 2020 Oct 2;2020:8830471. doi: 10.1155/2020/8830471. eCollection 2020. Dis Markers. 2020. PMID: 33082885 Free PMC article.
Cited by
-
Bioinformatics analysis of genomic and immune infiltration patterns in autism spectrum disorder.Ann Transl Med. 2022 Sep;10(18):1013. doi: 10.21037/atm-22-4108. Ann Transl Med. 2022. PMID: 36267781 Free PMC article.
-
Predictive Effect of System Inflammation Response Index for Progression of Chronic Kidney Disease in Non-Dialyzing Patient.J Inflamm Res. 2023 Nov 15;16:5273-5285. doi: 10.2147/JIR.S432699. eCollection 2023. J Inflamm Res. 2023. PMID: 38026247 Free PMC article.
-
MiRNA-133a-3p Attenuates Renal Tubular Epithelial Cell Injury via Targeting MALM1 and Suppressing the Notch Signaling Pathway in Diabetic Nephropathy.Cell Biochem Biophys. 2024 Sep;82(3):2401-2411. doi: 10.1007/s12013-024-01351-4. Epub 2024 Jun 15. Cell Biochem Biophys. 2024. PMID: 38878099
-
Insights into serum metabolic biomarkers for early detection of incident diabetic kidney disease in Chinese patients with type 2 diabetes by random forest.Aging (Albany NY). 2024 Feb 12;16(4):3420-3530. doi: 10.18632/aging.205542. Epub 2024 Feb 12. Aging (Albany NY). 2024. PMID: 38349886 Free PMC article.
-
New insights into renal lipid dysmetabolism in diabetic kidney disease.World J Diabetes. 2021 May 15;12(5):524-540. doi: 10.4239/wjd.v12.i5.524. World J Diabetes. 2021. PMID: 33995842 Free PMC article. Review.
References
-
- Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20:1–17. - PubMed
-
- Sweetser DA, Heuckeroth RO, Gordon JI. The metabolic significance of mammalian fatty-acid-binding proteins: abundant proteins in search of a function. Annu Rev Nutr. 1987;7:337–59. - PubMed
-
- Moore E, Bellomo R, Nichol A. Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: From the bench to clinical research to clinical practice. Minerva Anestesiol. 2010;76:425–40. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials